Ewa Paszkiewicz‐Kozik

Statistics

Publications

Citations

724

H-Index

Active since

2003

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Gdańsk Medical University

Instytut Hematologii i Transfuzjologi

Ankara University

National Hospital Organization

Ewa Paszkiewicz‐Kozik is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2003–2024

Publications

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli et al. · The Lancet Haematology · 2018 · 116 citations · Full text

Medicine, Immunology, Oncology +9

Degradation of NF-κB in T Cells by Gangliosides Expressed on Renal Cell Carcinomas

Mark Thornton, Daisuke Kudo, Patricia Rayman et al. · The Journal of Immunology · 2004 · 52 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways

Tanya Das, Gaurisankar Sa, Ewa Paszkiewicz‐Kozik et al. · The Journal of Immunology · 2008 · 42 citations

Life Sciences, Immunology, Oncology +17

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · Journal of Clinical Oncology · 2020 · 34 citations

Medicine, Oncology, Pharmacotherapy +17

1–5 of 18